Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism (original) (raw)

This paper investigates the use of percutaneous ethanol injection therapy (PEIT) as a non-surgical treatment for patients with primary hyperparathyroidism (p-HPT) who are either unwilling or ineligible for surgery. It presents findings from a study involving 19 high surgical risk patients, reporting a 58% curative rate and approximately 90% efficacy in preventing the need for surgical intervention. Compared to current medical therapies, PEIT shows improved biochemical outcomes, although its long-term results remain inferior to surgical options. The study suggests that smaller parathyroid glands and lower iPTH levels at diagnosis may correlate with better treatment outcomes, emphasizing the potential of PEIT as an established and cost-effective alternative therapy for this patient population.